Key result
Spironolactone treatment for 12 months in peritoneal dialysis patients did not significantly alter echocardiographic indices, blood pressure, or most biochemical markers, but significantly increased osteopontin levels.
Why the study?
Does spironolactone 50 mg daily improve cardiovascular system status and biomarkers of inflammation, fibrosis, thrombosis, and mineral-bone metabolism in peritoneal dialysis patients?
Cohort (n=37)
No
Does spironolactone 50 mg daily improve cardiovascular system status and biomarkers of inflammation, fibrosis, thrombosis, and mineral-bone metabolism in peritoneal dialysis patients?
In patients on peritoneal dialysis, 12 months of spironolactone 50 mg daily was safe without causing hyperkalemia, but did not significantly improve echocardiographic indices, arterial stiffness, or most biomarkers.
Answers are grounded in this paper and cite their sources.
Suggests limited cardiovascular benefit for spironolactone in peritoneal dialysis; leaves open whether larger randomized trials might.
BACKGROUND: High aldosterone level may contribute to pathogenesis of hypertension, vessels damage and cardiovascular system deterioration in chronic kidney disease patients. Besides its classical action via mineralocorticoid receptor, aldosterone is also involved in cell growth, inflammation, oxidative stress, endothelial dysfunction and exerts fibroproliferative effects. The aim of the study was to assess whether aldosterone antagonist treatment may influence serum level of inflammatory, fibrosis, thrombosis and mineral-bone metabolism markers in peritoneal dialysis (PD) patients and blood pressure, aortic stiffness, echocardiographic indices after 12 months of treatment. METHODS: Twenty-two patients on PD were assigned to spironolactone treatment in dose of 50 mg daily during 12 months. Fifteen PD patients were assigned to control group. Echocardiographic indices, PVW, SBP, DBP (mean values from ABPM) and biochemical parameters such as: aldosterone, osteopontin, IL-6, selectin-P, TGF-β, PTH, MMP-2 were performed at the beginning and after 12 months in spironolactone and control group. RESULTS: There were no statistically significant differences in echocardiographic indices, PWV, BP (ABPM readings) and biochemical markers: MMP-2, serum aldosterone, TGF-β, IL-6, selectin-P, PTH level after 12 months of spironolactone treatment. There was statistically significant rise in osteopontin level after 12 months of spironolactone treatment. Episodes of life-threatening hyperkalemia were not reported. CONCLUSIONS: Aldosterone antagonists use in PD patients seems to be safe. Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients. Further studies are required to determine relationship between mineralocorticoid receptor blockade and mineral-bone disturbances in PD patients.
No takes yet. Share an insight, caveat, or question.
Donderski et al. (2017) conducted a cohort in Peritoneal dialysis (n=37). Spironolactone vs. Standard care (ACE-I or ARBs) was evaluated on Echocardiographic indices, arterial stiffness, blood pressure, and biochemical markers. Spironolactone treatment for 12 months in peritoneal dialysis patients did not significantly alter echocardiographic indices, blood pressure, or most biochemical markers, but significantly increased osteopontin levels.
Synapse has enriched 10 related papers. Consider them for comparative context: